F351 Phase III enrollment completed ahead of schedule for HBV liver fibrosis

GYRE THERAPEUTICS, INC.

Beijing Continent completed subject enrollment for F351 Phase III trial in China, more than two months ahead of initial expectation.
Trial aims to confirm efficacy of F351 for liver fibrosis associated with chronic hepatitis B; safety comparable to Phase II.
F351 received Breakthrough Therapy designation from NMPA in 2021; top-line data expected after 52-week data collection.
BC, the trial sponsor, will become a subsidiary of Catalyst Biosciences per prior October 24 disclosure; no change to GNI consolidation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.